Arctic Vision develops gene and cell therapies for various ophthalmic conditions, including glaucoma, inherited retinal degeneration, and corneal endothelial dysfunction, utilizing advanced delivery methods such as AAV-based systems and suprachoroidal space injections. Their therapies aim to improve patient outcomes by addressing the limitations of current treatments, such as the inefficiency of cornea transplants and the need for new mechanisms to prevent vision loss.

BLAZE offers a software suite that provides point-of-sale, inventory management, and e-commerce solutions specifically designed for cannabis dispensaries and delivery services. This technology streamlines operations and enhances compliance, enabling businesses to efficiently manage sales, inventory, and customer interactions in a highly regulated industry.

Engrail Therapeutics develops precision-targeted therapeutics for patients with life-limiting neurological disorders by leveraging expertise in molecular mechanisms and neurocircuitry. The company aims to provide effective treatments that address the unmet medical needs of individuals suffering from these debilitating conditions.

FusionZ utilizes AI-driven contract analysis to streamline the generation and review of renewable energy contracts, enhancing clarity and compliance for legal and engineering teams. The platform minimizes risks, accelerates negotiations, and automates risk assessments, making complex agreements more accessible and manageable.

Grail develops the Galleri® test, a multi-cancer early detection (MCED) blood test that analyzes DNA methylation patterns to identify signals from various cancers that lack standard screening methods. This technology enables earlier cancer detection, potentially improving treatment outcomes and reducing mortality rates.

Heranova develops a portfolio of non‑invasive, laboratory‑validated diagnostics for women’s reproductive health, including HerResolve™—a blood‑based test that confirms endometriosis—and a suite of microbiome, receptivity, and ovarian reserve assays that guide fertility treatment. By delivering accurate, cloud‑based results to obstetrician‑gynecologists and fertility clinics, the company enables earlier diagnosis, reduces unnecessary surgeries, and personalizes IVF planning to improve outcomes.

SanReno Therapeutics develops and manufactures targeted therapies for chronic kidney disease, utilizing advanced pharmacological techniques to enhance renal function and patient outcomes. The company addresses the significant unmet medical need for effective treatments in a condition that affects millions globally, improving quality of life and reducing healthcare costs.

Vaxcyte is developing high-fidelity vaccines using its XpressCF™ cell-free protein synthesis platform to produce broad-spectrum conjugate vaccines that target invasive bacterial diseases, including pneumococcal infections and Group A Strep. The company's lead candidate, VAX-24, is a 24-valent vaccine designed to prevent invasive pneumococcal disease, addressing the limitations of existing vaccines that fail to cover non-vaccine strains.

Windward Bio is a clinical-stage biotechnology company focused on developing treatments for advanced immunological conditions. The company's lead program, WIN378, is a long-acting anti-TSLP monoclonal antibody currently in Phase 2 trials for asthma. Windward Bio is building a pipeline of long-acting bispecific antibodies targeting validated biology in respiratory and dermatological diseases.

Zenas BioPharma is developing Obexelimab, a bifunctional monoclonal antibody that targets CD19 and FcγRIIb to suppress B cell activity, which is a key factor in autoimmune diseases. The company aims to provide effective therapies for patients suffering from these conditions, addressing significant unmet medical needs in immunology.